Physician profile
Timothy Lindquist
NPI 1124281431
$1,390.14
in general payments reported to CMS, 2019-2025
17 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2020: $98.92 · 2021: $42.35 · 2022: $14.43 · 2023: $452 · 2024: $457 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,050.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $212.40 | 2019-2021 | |
| Abbvie INC. | $181.59 | 2023-2025 | |
| Rxsight INC | $145.47 | 2023-2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Johnson & Johnson Surgical Vision, INC. | $139.64 | 2023-2024 | Tecnis Iol, Tecnis Simplicity, Tecnis Iol |
| Biotissue Holdings INC. | $133.41 | 2024 | |
| Rayner Intraocular Lenses Limited | $120.87 | 2023-2025 | Rayone Emv, Rayone Spheric, Rayone Aspheric |
| Bausch & Lomb Americas INC. | $104.21 | 2023-2024 | Vyzulta, Miebo, Zylet |
| Sun Pharmaceutical Industries INC. | $85.27 | 2023-2025 | Cequa |
| Carl Zeiss Meditec, INC. | $73.28 | 2019 | |
| Ocular Therapeutix, INC. | $45.34 | 2023 | Dextenza |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Mallinckrodt Hospital Products INC. | $38.20 | 2024 | Acthar |
| Novartis Pharmaceuticals Corporation | $22.48 | 2023 | |
| Tarsus Pharmaceuticals, INC. | $20.22 | 2024 | Xdemvy |
| Allergan, INC. | $14.43 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $13.70 | 2023 | Tyrvaya |
| Travere Therapeutics, INC. | $0.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Lindquist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.